INFINITI
1 year ago
On May 10, 2023, Acorda Therapeutics, Inc. (the โCompanyโ) issued a press release announcing that the Company will make a cash interest payment of approximately $6.2 million in satisfaction of the interest payment due on June 1, 2023, as provided for under the indenture governing the Companyโs 6.00% Convertible Senior Secured Notes due 2024 (the โNotesโ). The Company will make the interest payment using cash that was placed in escrow when the Notes were issued, which is reported on the Companyโs balance sheet as restricted cash. The June 1 payment is the last payment in which the Company has the option to pay in cash or shares of its common stock. All future payments will be made in cash. A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
cash4
2 years ago
I hope everyone votes against the R/S as I will, if I go bankrupt so should They, ...the reason they did not want to pay their debts is because bankruptcy will protect them from debts, therefore those they owe money to should exercise a hostile takeover and fire these clowns all together.
As of now the Market Cap dropped to 17 mil, if they want the stock above $1 they should announce a Buyback, they just got $16 mil in their bank the other day, always on the backs of lenders and shareholders, I'm so pissed with these crooks.
The same story with fly-by-night corporations, the losses are public but the profits are private, FOH,...they never share profits, only deficit.
Give me $16 mil and by the end of the trading day I would fire all of them on Zoom.
cash4
2 years ago
This company is run by a bunch of clowns. You announce a Reverse Split proposal when you break $1 in just one day of trading from 34 cents, then you blackmail the shareholders to approve in voting if not you have to declare bankruptcy, when the company got more money awarded than the entire Market Cap is worth ? Bunch of assholes.
I wish some smart wale just buys up the entire free trading float and leaves them with just the 26% owned by the insiders to take this company to the next level.
24 mil shares float, what is the ratio going to be ? They want this stock to have only 2 Mil float ? Are they that stupid, 1st they announce they won't pay debts with shares to protect the shareholders from dilution and how's a Reverse Split going to protect us, morons.
Invest-in-America
2 years ago
ACOR: Simply follow BARCHART (free, see link below); & FIDELITY has an excellent (free) daily list of the top running stocks, which they call "MARKET MOVERS". However, in order to SEE Fidelity's important list, you have to OPEN an account with them --- but NO DEPOSIT MONEY is required (ever),
https://www.barchart.com/investing-ideas/penny-stocks?orderBy=percentChange5d&orderDir=desc
//////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
Invest-in-America
2 years ago
ACOR: "Is this good?" Peeps love anything to do with LAWSUITS, bankruptcies, fraud investigations, etc., about ANY company. And, since evidently ACOR just WON a civil action of some nature, well, to the MOON --- at least for THIS particular day. (At this writing, ACOR is DOWN by 8.25% 'after hours', which is no big deal, per se.)
In any event, ACOR closed this day near the TOP of the following (very influential) LIST --- which everyone should follow every day. (Toss-away your silly 'Scanners'; stop 'following' mutha-duckas; & simply let BARCHART make you some bucks!!)
https://www.barchart.com/investing-ideas/penny-stocks?orderBy=percentChange5d&orderDir=desc
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
crudeoil24
2 years ago
"This award will allow Acorda to obtain more competitive market rates for the supply of AMPYRA, significantly reducing our cost of goods and meaningfully increasing the product's value to the company," said Ron Cohen, M.D., Acorda's President and CEO. "This will also help Acorda to continue to provide its customary high level of support for Ampyra, ensuring that as many people with MS as possible may benefit from it."